Multinational phase 3 study of acalabrutinib versus ibrutinib for previously treated CLL

Increased selectivity of the Bruton tyrosine kinase inhibitor acalabrutinib versus ibrutinib may improve tolerability. A multinational phase 3 study compared acalabrutinib with ibrutinib for previously treated CLL. The median PFS was 38.4 months in both arms. Acalabrutinib was associatied with less cardiotoxicity and fewer discontinuations due to adverse events compared with ibrutinib.